WO2016165495A1

WO2016165495A1 - Topical medicine for treating lung cancer and preparation method thereof

Info

Publication number: WO2016165495A1
Application number: PCT/CN2016/074652
Authority: WO
Inventors: 马建
Original assignee: 马建
Priority date: 2015-04-13
Filing date: 2016-02-26
Publication date: 2016-10-20
Also published as: CN104707047B; CN104707047A

Abstract

Disclosed are a topical medicine for treating lung cancer and a preparation method thereof. The raw materials of the medicine comprise ganoderma lucidum, codonopsis pilosula, rhizoma atractylodis macrocephalae, natural bezoar, radix ophiopogonis, barbed skullcap herb, quercetin, rhizoma sparganii, seaweed, myrrh, agrimonia pilosa, pinellia ternata, forsythia suspensa, solanum lyratum thunb, bryozoatum and semen armeniacae amarae; the raw materials of the medicine may also comprises fructus cnidii, asiatic moonseed rhizome and dandelion.

Description

External medicine for treating lung cancer and preparation method thereof

Technical field

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a topical medicine for treating lung cancer and a preparation method thereof.

Background technique

Lung cancer is one of the most malignant tumors with the fastest growth in morbidity and mortality and the greatest threat to population health and life. In the past 50 years, the incidence and mortality of lung cancer have been significantly increased in many countries. The incidence and mortality of lung cancer in males accounted for the first place among all malignant tumors. The incidence rate of females ranked second and the mortality rate ranked second. The etiology of lung cancer is still not completely clear. A large amount of data indicates that long-term large-scale smoking has a very close relationship with the occurrence of lung cancer. Previous studies have shown that the probability of lung cancer in a long-term large number of smokers is 10 to 20 times that of non-smokers. The younger the age of smoking, the higher the risk of lung cancer.

Lung cancer has become a major killer of human health. According to domestic and foreign literature reports, the global incidence of lung cancer is as high as 205,020, accounting for about 14% of new tumor cases worldwide, with high incidence and high mortality. Under the influence of environmental pollution, smoking, ionizing radiation, occupational exposure and viral infection, the incidence and mortality of lung cancer have been rising, increasing at a rate of 0.5% per year, and with the increase in the number of young people smoking. Lung cancer is getting younger. According to the results of the death survey of residents of the Ministry of Health in China in 2008, lung cancer has replaced liver cancer as the first cause of malignant tumor death in China. Therefore, the diagnosis and treatment of lung cancer has attracted enough attention from the medical community.

Lung cancer is divided into small cell lung cancer (SCLC, 20%) and non-small cell lung cancer (NSCLC, 80%), and its pathogenesis is complicated. At present, the treatment of lung cancer at home and abroad is mainly surgery, radiotherapy and chemotherapy, but these methods are easy to cause serious side effects on the normal organs of patients, and the prognosis and survival rate are poor. Traditional Chinese medicine featuring "Xie Xie Fu Zheng" has played a huge role in the treatment of lung cancer. The effect is not only consolidated, but also has little side effects and does not cause great harm to the body. It can be used together with chemotherapy to increase the effect and reduce toxicity. Therefore, it is a hot and difficult point in oncology research to find and develop high-efficiency and low-toxic anti-lung cancer drugs from traditional Chinese medicines and natural medicines. Patent 2005100156241 discloses an adjuvant treatment for advanced lung cancer, such as Astragalus, Codonopsis pilosulae, Radix Adenofolia, Ophiopogon japonicus, Agrimony, Gymnosperm, Sabina, Hedyotis diffusa, Fritillaria, Aster, Campanulaceae, Bitter Almond The licorice Chinese herbal medicine extract is made of raw materials. The invention has a large dosage and a long treatment period. Although there are many methods in the prior art, it is difficult to find an effective method.

Summary of the invention

An object of the present invention is a topical medicine for treating lung cancer, which comprises the following components: Ganoderma lucidum, Codonopsis, Atractylodes, natural bezoar, Ophiopogon japonicus, Scutellaria barbata, Quercetin, Trigonium, seaweed, Myrrh, Agrimony, Pinellia, Forsythia, Baiying, Sea Pumice and Bitter Almond.

The drug also includes Cnidium, North Bean Root and Dandelion.

The medicine is divided into parts by weight: 0.5-1 parts of Ganoderma lucidum, 2-3.5 parts of Codonopsis pilosula, 1-2 parts of Atractylodes macrocephala, 0.6-0.8 parts of natural bezoar, 1-1.5 parts of Ophiopogon japonicus, 2-3 parts of Scutellaria barbata L. 1-2 parts, 2.5-3 parts of triangles, 2.5-3.5 parts of seaweed, 1-2 parts of myrrh, 1-3 parts of Agrimony, 1-1.5 parts of Pinellia, 1.2-1.6 parts of Forsythia, Baiying 3 - 4 parts, 3-3.5 parts of sea pumice, 0.5-2 parts of bitter almond, 0.5-0.6 parts of Cnidium, 1-1.8 parts of B. chinensis and 1-2 parts of dandelion.

The drug is divided into parts: 0.5 parts of Ganoderma lucidum, 3 parts of Codonopsis, 2 parts of Atractylodes, 0.7 parts of natural bezoar, 1 part of Ophiopogon japonicus, 2 parts of Scutellaria barbata L., 1.5 parts of quercetin, 2.5 parts of trigonyl, 3 parts of seaweed. 2 parts of myrrh, 2 parts of Agrimony, 1.5 parts of Pinellia, 1.5 parts of Forsythia, 4 parts of Baiying, 3 parts of sea pumice, 1 part of bitter almond, 0.5 part of Cnidium, 1.6 parts of North bean root and 2 parts of dandelion .

The preparation method of the external medicine for treating lung cancer comprises the following steps:

(1) Ultrafine pulverization of Ganoderma lucidum, passing through a 100 mesh sieve, and extracting twice under reflux to obtain extraction Liquid and ganoderma lucidum dregs;

(2) taking 50 parts of water and 5 parts of xanthan gum, mixing and heating to 100 ° C;

(3) taking 5 parts of glyceryl stearate, 3 parts of squalane and 4 parts of stearyl polyether mixed and heated to 90 ° C;

(4) mixing the solution obtained in the step (2) and the step (3), taking the ganoderma lucidum residue of the step (1), mixing with the drug component other than the Ganoderma lucidum of claim 1, stirring, and boiling for 1 hour or more, and obtaining the medicine. The soup is mixed with the extract of step (1), and the mixing temperature is 60 ° C;

(5) After mixing, cool down, air dry, fill, and get the finished product.

The solvent extracted under reflux was ethanol and ethyl acetate; the volume ratio of ethanol to ethyl acetate was 5:1.

The stirring speed is 500 rpm/min or more.

The speed of the cooling is 1 ° C / min or more.

The invention adopts the leading small molecule cutting technology, and the ultrafine pulverization can pulverize the ganoderma lucidum into fine particles. Using the small molecule cutting technique, the obtained product has a small particle size, and the active ingredient in the drug is sufficiently released in the form of small molecules. It does not contain large sections of plant fiber that are difficult to absorb through the skin, and the product does not contain heavy metals. The drug can be directly applied to the affected area, and the active ingredient can be directly transdermally absorbed without a carrier, and can be quickly targeted to reach the affected part. After reflux extraction, the functional ingredients in Ganoderma lucidum can be effectively extracted, and the dregs can be decoctioned to maximize the nutrients in Ganoderma lucidum. The pharmaceutical composition of the present invention produces a synergistic effect, and can function to prevent tumors, inhibit growth of cancer cells, and kill cancer cells. The invention can also significantly increase the number of white blood cells in the patient and improve immunity. At the same time, the invention has no toxic and side effects, is suitable for long-term use, and eradicates diseases.

detailed description

Example 1

(1) Ultrafine pulverization of 0.5 parts of Ganoderma lucidum, passing through a 100 mesh sieve, and refluxing twice, the solvent is ethanol and ethyl acetate; the volume ratio of ethanol to ethyl acetate is 5:1, and the extract and the ganoderma lucidum residue are obtained. ;

(4) mixing the solution obtained in the step (2) and the step (3), taking the ganoderma lucidum residue of the step (1), 3 parts of Codonopsis pilosula, 2 parts of Atractylodes, 0.7 parts of natural bezoar, 1 part of Ophiopogon japonica, and 1 part of Scutellaria barbata. 1.5 parts, quercetin 1.5 parts, 2.5 parts of trigonal, 3 parts of seaweed, 2 parts of myrrh, 2 parts of Agrimony, 1.5 parts of Pinellia, 1.5 parts of Forsythia, 4 parts of Baiying, 3 parts of sea pumice, 1 bitter almond 0.5 parts of Cnidium, 1.6 parts of B. chinensis and 2 parts of dandelion were mixed and stirred, stirred at 500 rpm/min, and decocted for 1 hour. The obtained broth was mixed with the extract of step (1) at a mixing temperature of 60. °C;

(5) After mixing, the temperature is lowered, the speed of cooling is 1 °C/min, air drying, filling, and the finished product is obtained.

Example 2

(4) mixing the solution obtained in the step (2) and the step (3), taking the ganoderma lucidum residue of the step (1), 3.5 parts of Codonopsis pilosula, 1 part of Atractylodes, 0.6 parts of natural bezoar, 1.5 parts of Ophiopogon japonicus, and Scutellaria barbata 2 2 parts, quercetin 2 parts, 3 parts of trigonal, 2.5 parts of seaweed, 1 part of myrrh, 1 part of Agrimony, Pinellia 1.5 parts, 1.2 copies of Forsythia, 3 parts of Baiying, 3.5 parts of sea pumice, 0.5 parts of bitter almond, 0.5 part of Cnidium, 1.8 parts of B. chinensis and 2 parts of dandelion were mixed and stirred, stirring speed was 600 rpm/min, boiling 100分钟, the obtained broth is mixed with the extract of step (1), the mixing temperature is 60 ° C;

(5) After mixing, the temperature is lowered, the speed of cooling is 1.5 ° C / min, air drying, filling, and the finished product is obtained.

Example 3

(1) Ultrafine pulverization of 0.8 parts of Ganoderma lucidum, passing through a 100 mesh sieve, and extracting twice under reflux, the solvent is ethanol and ethyl acetate; the volume ratio of ethanol to ethyl acetate is 5:1, and the extract and the ganoderma lucidum residue are obtained. ;

(4) mixing the solution obtained in the step (2) and the step (3), taking the ganoderma lucidum residue of the step (1), 2 parts of Codonopsis pilosula, 2 parts of Atractylodes, 0.8 parts of natural bezoar, 1 part of Ophiopogon japonicus, and Scutellaria barbata. 1 part, quercetin 1 part, 2.5 parts of trigonal, 3.5 parts of seaweed, 2 parts of myrrh, 3 parts of Agrimony, 1 part of Pinellia, 1.6 parts of Forsythia, 4 parts of Baiying, 3 parts of sea pumice, Bitter almond 2 0.6 parts of Cnidium, 1 part of B. chinensis and 1 part of dandelion were mixed and stirred, stirred at 700 rpm/min, and decocted for 1.5 hours. The obtained broth was mixed with the extract of step (1) at a mixing temperature of 60. °C;

(5) After mixing, the temperature is lowered, the speed of cooling is 2 °C/min, air drying, filling, and the finished product is obtained.

Example 4

(1) Ultrafine pulverization of 0.6 parts of Ganoderma lucidum, passing through a 100 mesh sieve, and extracting twice under reflux, the solvent is ethanol and ethyl acetate; the volume ratio of ethanol to ethyl acetate is 5:1, and the extract and the ganoderma lucidum residue are obtained. ;

(4) Mixing the solutions obtained in the step (2) and the step (3), taking the ganoderma lucidum residue of the step (1), 2.5 parts of Codonopsis pilosula, 1.8 parts of Atractylodes, 0.65 parts of natural bezoar, 1.2 parts of Ophiopogon japonica, and Scutellaria barbata 2.3 1 part, quercetin 1 part, 2.9 parts of trigonal, 3.4 parts of seaweed, 1.6 parts of myrrh, 2.5 parts of Agrimony, 1.4 parts of Pinellia, 1.5 parts of Forsythia, 3.2 parts of Baiying, 3 parts of sea pumice, 1.5 bitter almond 0.6 parts of Cnidium, 1.6 parts of B. chinensis and 1.4 parts of dandelion were mixed and stirred, stirred at 550 rpm/min, and boiled for 80 minutes. The obtained broth was mixed with the extract of step (1) at a mixing temperature of 60. °C;

(5) After mixing, the temperature is lowered, the speed of cooling is 1.8 ° C / min, air drying, filling, and the finished product is obtained.

Example 5

(1) One part of Ganoderma lucidum was subjected to ultrafine pulverization, passed through a 100 mesh sieve, and extracted twice under reflux. The solvent was ethanol and ethyl acetate; the volume ratio of ethanol to ethyl acetate was 5:1, and the extract and the ganoderma lucidum residue were obtained. ;

(4) mixing the solution obtained in the step (2) and the step (3), taking the ganoderma lucidum residue of the step (1), 3 parts of Codonopsis pilosula, 2 parts of Atractylodes, 0.6 parts of natural bezoar, 1.4 parts of Ophiopogon japonicus, and Scutellaria barbata 2.5 2 parts, quercetin 2 parts, 3 parts of trigonal, 3 parts of seaweed, 1.5 parts of myrrh, 1.5 parts of Agrimony, 1 part of Pinellia, 1.3 parts of Forsythia, 3.5 parts of Baiying, 3.5 parts of sea pumice, 1.5 bitter almond Mix, 0.6 parts of Cnidium, 1 part of B. chinensis and 1.5 parts of dandelion, stir, stir at 650 rpm/min, and decoct for 1.5 hours. The obtained broth is mixed with the extract of step (1) at a mixing temperature of 60. °C;

Patent 12005100156241 is taken as comparative example 1.

A/J mice of 6-8 weeks old, 10 rats in each group, were intraperitoneally injected with 3,4-benzopyrene-corn oil solution at a dose of 10 mg/kg body weight to induce lung cancer. They were divided into three groups: Example 1 group, Example 2 group, and Comparative group 1 at a dose of 0.5 mg/kg body weight for 150 days. The mice were sacrificed by cervical dislocation, and formalin was injected into the lungs to calculate the number of nodules on the surface of the lungs.

Table 1

	实施例1Example 1	实施例2Example 2	对比例1Comparative example 1
肺表面结节数Number of pulmonary nodules	44	55	24twenty four

It can be seen from Table 1 that the number of pulmonary surface nodules of Example 1 and Example 2 of the present invention is significantly less than that of Comparative Example 1, which can effectively inhibit the growth of lung cancer cells and achieve the purpose of preventing and treating lung cancer.

The A549 lung cancer cells in logarithmic growth phase were dissociated, resuspended, cultured in 48-well plum plates, and 200 μl of culture medium was added to each well at a dose of 0.5/ml. The growth inhibitory effects of Example 1, Example 2 and Comparative Example 1 on tumor cells were measured.

Table 2

	实施例1Example 1	实施例2Example 2	对比例1Comparative example 1
肿瘤细胞生长抑制率Tumor cell growth inhibition rate	82.5％82.5%	79.6％79.6%	63.1％63.1%

As can be seen from Table 2, the tumor cell growth inhibition rates of Examples 1 and 2 were significantly higher than those of Comparative Example 1, and the proliferative activity of A549 lung cancer cells was effectively inhibited.

The detailed description of the present invention is intended to be illustrative of the preferred embodiments of the present invention, and is not intended to limit the scope of the invention. Within the scope of the technical solution.

Claims

A topical medicine for treating lung cancer, characterized in that the medicine comprises the following components: Ganoderma lucidum, Codonopsis pilosula, Atractylodes macrocephala, natural bezoar, Ophiopogon japonicus, Scutellaria barbata, Quercetin, Trigonium, Seaweed, Myrrh, Agrimony , Pinellia, forsythia, Baiying, sea pumice and bitter almond.
The external medicine for treating lung cancer according to claim 1, wherein the medicine further comprises Cnidium, North Bean Root and Dandelion.
The external medicine for treating lung cancer according to claim 1, wherein the medicine is 0.5-1 parts of Ganoderma lucidum, 2-3.5 parts of Codonopsis pilosula, 1-2 parts of Atractylodes macrocephala, and 0.6-0.8 parts of natural bezoar. 1-1.5 parts of Ophiopogon japonicus, 2-3 parts of Scutellaria barbata L., 1-2 parts of quercetin, 2.5-3 parts of trigonal, 2.5-3.5 parts of seaweed, 1-2 parts of myrrh, 1-3 parts of Agrimony, 1-1.5 parts of Pinellia, 1.2-1.6 parts of Forsythia, 3-4 parts of Baiying, 3-3.5 parts of sea pumice, 0.5-2 parts of bitter almond, 0.5-0.6 parts of Cnidium, 1-1.8 parts of North bean root and 1-2 servings of dandelion.
The medicine for treating lung cancer according to claim 1, wherein the medicine is 0.5 parts of Ganoderma lucidum, 3 parts of Codonopsis, 2 parts of Atractylodes, 0.7 parts of natural bezoar, 1 part of Ophiopogon japonicus, and Scutellaria barbata. 2 parts, 1.5 parts of quercetin, 2.5 parts of trigonal, 3 parts of seaweed, 2 parts of myrrh, 2 parts of Agrimony, 1.5 parts of Pinellia, 1.5 parts of Forsythia, 4 parts of Baiying, 3 parts of sea pumice, bitter almond 1 part, 0.5 part of Cnidium, 1.6 parts of North bean root and 2 parts of dandelion.
The method for preparing a topical medicament for treating lung cancer according to claim 1, comprising the steps of:

(1) Ultrafine pulverization of Ganoderma lucidum and reflux extraction twice to obtain an extract and a ganoderma lucidum dregs;

(2) taking 50 parts of water and 5 parts of xanthan gum, mixing and heating to 100 ° C;

(3) taking 5 parts of glyceryl stearate, 3 parts of squalane and 4 parts of stearyl polyether To 90 ° C;

(4) mixing the solution obtained in the step (2) and the step (3), taking the ganoderma lucidum residue of the step (1), mixing with the drug component other than the ganoderma lucidum of claim 1, stirring, and boiling for 1 hour or more. The soup is mixed with the extract of step (1), and the mixing temperature is 60 ° C;

(5) After mixing, cool down, air dry, fill, and get the finished product.
The method for preparing a topical medicament for treating lung cancer according to claim 5, wherein the solvent for reflux extraction is ethanol and ethyl acetate; and the volume ratio of ethanol to ethyl acetate is 5:1.
The method for producing a topical medicine for treating lung cancer according to claim 5, wherein the stirring speed is 500 rpm/min or more.
The method for producing a topical medicine for treating lung cancer according to claim 5, wherein the rate of temperature drop is 1 ° C/min or more.